674 related articles for article (PubMed ID: 27411022)
21. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
Weisel K; Wadlund AO; Gungor G; Dergarabetian E; Pacheco C; Masurkar N; Rodriguez-Otero P
Eur J Haematol; 2022 Oct; 109(4):388-397. PubMed ID: 35775385
[TBL] [Abstract][Full Text] [Related]
22. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
[TBL] [Abstract][Full Text] [Related]
23. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
24. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Engelhardt M; Ihorst G; Singh M; Rieth A; Saba G; Pellan M; Lebioda A
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e160-e175. PubMed ID: 33218965
[TBL] [Abstract][Full Text] [Related]
25. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.
Jurczyszyn A; Davila J; Kortüm KM; Jayabalan DS; Vij R; Fiala M; Milunovic V; Chim CS; Wiśniewska-Piąty K; Waszczuk-Gajda A; Crusoe E; Hajek R; Robak P; Raźny M; Zawirska D; Bittrich M; Nahi H; Liu J; Castillo JJ; Vesole DH
Leuk Lymphoma; 2019 Feb; 60(2):471-476. PubMed ID: 30033832
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
28. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
de Moraes Hungria VT; Martínez-Baños DM; Peñafiel CR; Miguel CE; Vela-Ojeda J; Remaggi G; Duarte FB; Cao C; Cugliari MS; Santos T; Machnicki G; Fernandez M; Grings M; Ammann EM; Lin JH; Chen YW; Wong YN; Barreyro P
Br J Haematol; 2020 Feb; 188(3):383-393. PubMed ID: 31392724
[TBL] [Abstract][Full Text] [Related]
29. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe.
Martínez-Lopez J; Bailey A; Lambert A; Luke E; Ribbands A; Erler-Yates N; Valluri S; Haefliger B; Gay F
Future Oncol; 2023 Oct; 19(31):2103-2121. PubMed ID: 37706245
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
31. Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
Fazzi R; Petrini I; Giuliani N; Morganti R; Carulli G; Dalla Palma B; Notarfranchi L; Galimberti S; Buda G
Front Immunol; 2020; 11():573156. PubMed ID: 33613510
[TBL] [Abstract][Full Text] [Related]
32. Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Cheong CS; Tengku K Aziz TAH; Anuar NA; Bee PC; Chin EFM; Khairullah S; Liong CC; Zamri Y; Gan GG
Asian Pac J Cancer Prev; 2024 Feb; 25(2):595-601. PubMed ID: 38415546
[TBL] [Abstract][Full Text] [Related]
33. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
34. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Medhekar R; Ran T; Fu AZ; Patel S; Kaila S
BMC Cancer; 2022 Aug; 22(1):901. PubMed ID: 35982416
[TBL] [Abstract][Full Text] [Related]
35. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
36. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
37. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
38. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM
BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403
[TBL] [Abstract][Full Text] [Related]
39. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Brown J; Liepa AM; Bapat B; Madhwani S; Lorenzen S; García-Foncillas J; Candrilli SD; Kaye JA
Eur J Cancer Care (Engl); 2020 Mar; 29(2):e13213. PubMed ID: 31883156
[TBL] [Abstract][Full Text] [Related]
40. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.
Gavriatopoulou M; Fotiou D; Koloventzou U; Roussou M; Migkou M; Ntanasis-Stathopoulos I; Kanellias N; Ziogas DC; Panagiotidis I; Gika D; Eleutherakis-Papaiakovou E; Terpos E; Kastritis E; Dimopoulos MA
Leuk Lymphoma; 2019 Mar; 60(3):619-628. PubMed ID: 30628505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
